A Lupus-like Syndrome Associated With Infliximab Therapy
Open Access
- 1 May 2003
- journal article
- case report
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 9 (3) , 176-178
- https://doi.org/10.1097/00054725-200305000-00005
Abstract
Summary. Infliximab, a chimeric monoclonal antibody targeting tumor necrosis factor alpha (TNF-α), is efficacious in the treatment of rheumatoid arthritis andKeywords
This publication has 25 references indexed in Scilit:
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Cytokines and systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2000
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- An in vitro assay for detection of glomerular binding IgG autoantibodies in patients with systemic lupus erythematosus.Journal of Clinical Investigation, 1996
- Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)Gastroenterology, 1995
- Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritisThe Lancet, 1994
- Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosusArthritis & Rheumatism, 1993
- TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?Rheumatology, 1992
- Tumour necrosis factor-α in murine autoimmune 'lupus' nephritisNature, 1988